[IMGN] ImmunoGen, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 1.64 Change: 0.08 (5.13%)
Ext. hours: Change: 0 (0%)

chart IMGN

Refresh chart

Strongest Trends Summary For IMGN

IMGN is in the medium-term down -57% in 5 months and down -82% below S&P in 1 year.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. It develops its products using its antibody-drug conjugates technology. The company offers Kadcyla, an antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer. Its product candidates include IMGN853, which is in Phase I clinical trials for the treatment of ovarian cancer, endometrial cancer, and other cancers; IMGN289 that is in Phase I clinical trials for treating squamous cell carcinoma of head and neck cancer, and non-small cell lung cancer; IMGN529, which is in Phase I clinical trials for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia; and IMGN779 that is in preclinical stage for treating acute myeloid leukemia. The company also develops compounds, such as AMG 172 that is in Phase I clinical trials for the treatment of clear cell renal cell carcinoma; AMG 595, which is in Phase I clinical trials for treating glioblastoma; BAY 94-9343 is in early clinical trials for the t

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 98.97% Sales Growth - Q/Q-76.34% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-42.42% ROE-95.13% ROI
Current Ratio5.22 Quick Ratio5.1 Long Term Debt/Equity Debt Ratio0.38
Gross Margin Operating Margin-71.01% Net Profit Margin-72.15% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.43 M Cash From Investing Activities-5.03 M Cash From Operating Activities-26.84 M Gross Profit
Net Profit-30.47 M Operating Profit-25.09 M Total Assets313.82 M Total Current Assets278.11 M
Total Current Liabilities35.81 M Total Debt Total Liabilities278.72 M Total Revenue12.61 M
Technical Data
High 52 week12.15 Low 52 week1.97 Last close2.05 Last change4.06%
RSI41.61 Average true range0.34 Beta1.43 Volume965.36 K
Simple moving average 20 days-23.29% Simple moving average 50 days-22.65% Simple moving average 200 days-63.67%
Performance Data
Performance Week-36.92% Performance Month-18.97% Performance Quart-63.72% Performance Half-63.26%
Performance Year-80.97% Performance Year-to-date-57.29% Volatility daily10.12% Volatility weekly22.63%
Volatility monthly46.37% Volatility yearly160.63% Relative Volume259.72% Average Volume4.09 M
New High New Low


2019-06-03 18:20:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunoGen, Inc. IMGN

2019-06-02 09:30:01 | Why Is ImmunoGen IMGN Down 26% Since Last Earnings Report?

2019-05-29 16:52:11 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunoGen, Inc. IMGN

2019-05-26 17:03:35 | The Week Ahead In Biotech: ASCO Presentations In The Spotlight

2019-05-22 18:10:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunoGen, Inc. IMGN

2019-05-22 11:34:03 | Biotech Stock Roundup: Label Expansion for CELG's Drugs, Setback for IMGN

2019-05-18 15:18:23 | Bulls And Bears Of The Week: Apple, Chevron, FedEx, Uber And More

2019-05-17 13:35:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunoGen, Inc. IMGN

2019-05-16 16:35:08 | ImmunoGen Plunges as FDA Recommends New Study for Lead Drug

2019-05-16 11:05:04 | What Analysts Recommend for IMGN after Its Q1 Results

2019-05-16 09:34:37 | Why Immunogen Was Down by More than 30% on May 15

2019-05-15 17:43:56 | SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunoGen, Inc. IMGN

2019-05-15 17:01:00 | ImmunoGen Announces Mature Data from FORWARD II Expansion Cohort Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Ovarian Cancer

2019-05-15 16:35:00 | Why The Children's Place, Agilent Technologies, and Immunogen Slumped Today

2019-05-15 11:42:00 | Why ImmunoGen Shares Are Crashing Today

2019-05-15 09:31:00 | ImmunoGen Plunges as FDA Rejects Fast-Track Approval for Cancer Drug

2019-05-15 08:22:00 | ImmunoGen stock down more than 30% after FDA suggests conducting new Phase 3 trial for ovarian cancer drug

2019-05-15 06:30:00 | ImmunoGen Provides Regulatory Update on Mirvetuximab Soravtansine Monotherapy in Ovarian Cancer

2019-05-06 09:44:01 | ImmunoGen IMGN Misses on Earnings & Revenues in Q1

2019-05-05 20:16:24 | Is ImmunoGen, Inc. IMGN A Good Stock To Buy?

2019-05-03 21:53:14 | Edited Transcript of IMGN earnings conference call or presentation 3-May-19 12:00pm GMT

2019-05-03 15:08:54 | Immunogen Inc IMGN Q1 2019 Earnings Call Transcript

2019-05-03 07:45:11 | ImmunoGen IMGN Reports Q1 Loss, Lags Revenue Estimates

2019-05-03 06:36:17 | ImmunoGen: 1Q Earnings Snapshot

2019-05-03 06:30:00 | ImmunoGen Reports Recent Progress and First Quarter 2019 Financial Results

2019-05-02 11:44:50 | ImmunoGen, Inc. NASDAQ:IMGN: What Are The Future Prospects?

2019-04-26 10:30:02 | Analysts Estimate ImmunoGen IMGN to Report a Decline in Earnings: What to Look Out for

2019-04-18 16:30:00 | ImmunoGen Announces Conference Call to Discuss Its First Quarter 2019 Operating Results

2019-04-15 13:49:47 | ImmunoGen Stock Is in Trouble Going Into Earnings

2019-04-08 17:16:00 | Here's Why ImmunoGen Tumbled 43% in March

2019-03-26 15:48:38 | Do Directors Own ImmunoGen, Inc. NASDAQ:IMGN Shares?

2019-03-12 08:56:12 | Options Traders Expect Huge Moves in ImmunoGen IMGN Stock

2019-03-10 09:30:01 | ImmunoGen IMGN Down 50.2% Since Last Earnings Report: Can It Rebound?

2019-03-06 12:22:06 | ImmunoGen Failure Casts a Shadow on Antibody-Drug Conjugates

2019-03-06 12:05:00 | Four Biotech Stocks Setting The Standard on Wednesday

2019-03-06 10:26:03 | Biotech Stock Roundup: BIIB to Acquire Nightstar, Other Pipeline News & More

2019-03-04 23:38:04 | Immunogen Ovarian Cancer Drug Fails in Phase III, Stock Sinks

2019-03-04 08:06:31 | Why ImmunoGen Tanked on Friday

2019-03-02 12:48:05 | Immunogen Inc IMGN Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-03-01 13:45:00 | Immunogen Tanks After Ovarian Cancer Drug Study Fails to Meet Endpoint

2019-03-01 12:13:42 | Why ImmunoGen Stock Is Crashing Today

2019-03-01 08:08:23 | Shares of Waltham drugmaker ImmunoGen crater after late-stage trial fail

2019-03-01 06:51:00 | Immunogen's stock loses nearly half its value after trial of cancer treatment fails to meet primary endpoint

2019-03-01 06:38:56 | ImmunoGen's ovarian cancer drug fails in late-stage study

2019-03-01 06:30:00 | ImmunoGen Announces Top-Line Results from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer

2019-02-27 17:14:00 | Why ImmunoGen Tumbled 20.3% Today

2019-02-27 16:31:00 | ImmunoGen Announces Multiple Presentations at AACR Annual Meeting

2019-02-22 07:40:00 | Factors of Influence in 2019, Key Indicators and Opportunity within Apple, United Continental, ImmunoGen, CymaBay Therapeutics, Granite Construction, and Flotek Industries — New Research Emphasizes Economic Growth

2019-02-21 08:00:00 | Healthcare Companies Investors are Watching

2019-02-18 14:19:27 | How ImmunoGen, Inc. NASDAQ:IMGN Could Add Value To Your Portfolio